Every 424B that enGene Therapeutics Inc. (ENGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ENGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENGN filings page.
enGene Holdings Inc. is offering up to $100,000,000 of common shares in an at‑the‑market (ATM) program to be sold from time to time through Leerink Partners LLC as sales agent.
The sales agent may sell shares on Nasdaq (symbol ENGN) using commercially reasonable efforts and will receive commissions of up to 3.0% of gross sales. The prospectus supplement cites a last reported sale price of $8.71 per share on March 5, 2026. The company reported 66,989,466 common shares outstanding as of March 5, 2026, and the prospectus shows a pro forma example of up to 78,470,522 shares outstanding assuming sale of 11,481,056 shares at $8.71. Proceeds, if any, will be used primarily to fund clinical development of detalimogene and for general corporate purposes.
enGene Holdings Inc. (ENGN) launched a primary offering of 12,558,823 common shares and pre-funded warrants to purchase 2,735,295 common shares. The shares were priced at $8.50 and the pre-funded warrants at $8.4999 (with a $0.0001 exercise price). Gross proceeds are $129,999,729.47, with underwriting discounts of $7,800,000.18 and proceeds to enGene before expenses of $122,199,729.29. The underwriters have a 30-day option to buy up to 2,294,117 additional shares.
Net proceeds are estimated at approximately $121.77 million, or approximately $140.10 million if the option is fully exercised. The company plans to use the funds to advance clinical development of its lead gene therapy, detalimogene, prepare commercial infrastructure for a potential launch, and for general corporate purposes. Pre-funded warrants are immediately exercisable, do not expire, include a 9.99% beneficial ownership cap (adjustable up to 19.99% after 61 days), and will not be listed. Common shares outstanding were 52,019,362 as of November 11, 2025.
enGene Holdings Inc. (ENGN) launched a preliminary prospectus supplement for a primary offering of common shares pursuant to its shelf registration. The common shares trade on Nasdaq under “ENGN”; the last reported sale price was $8.82 per share on November 11, 2025.
The company plans to use net proceeds to fund continued clinical development of its lead gene therapy, detalimogene voraplasmid, prepare commercial infrastructure for a potential launch, and for general corporate purposes. As of October 31, 2025, cash, cash equivalents and short‑term investments were $202.4 million. The filing includes a 30‑day option for underwriters to purchase additional shares and a 90‑day lock‑up for the company, directors and officers. No sales will be made in Canada or knowingly to Canadian residents.
enGene is an emerging growth and smaller reporting company. In updated Phase 2 LEGEND data for BCG‑unresponsive NMIBC with CIS, Post‑Protocol Amendment Patients showed a complete response rate of 63% (any time; 95% CI: 51–74), 56% at 3 months (95% CI: 44–68) and 62% at 6 months (95% CI: 46–76). Shares outstanding were 52,019,362 as of November 11, 2025.